^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Pancreatic Cancer
    Drug:dordaviprone (ONC201) (AKT inhibitor, ERK inhibitor, ClpP agonist, DRD2 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cell Death Dis
    Title:

    Gemcitabine elaidate and ONC201 combination therapy inhibits pancreatic cancer in a KRAS mutated syngeneic mouse model

    Published date:
    07/11/2023
    Excerpt:
    We evaluated the efficacy of L_GEM and ONC201 in PanCan cells, and “KrasLSL-G12D; p53LoxP; Pdx1-CreER (KPC) triple mutant xenograft tumor-bearing mice....Compared to L_GEM monotherapy, the combination of ONC201 and L_GEM significantly reduced the tumor size...The number of Ki67-positive cells in tumor tissues of both control and treatment groups showed that the combination significantly suppressed tumor cell proliferation...
    Secondary therapy:
    gemcitabine
    DOI:
    https://doi.org/10.21203/rs.3.rs-3108907/v1